| |
 Science
Yasuhiro Hashimoto, M.D.
President & CEO, MediBIC Group
President, MediBIC
President, MediBIC Pharma
President, Asia Private Equity Capital
Executive Director, Site Quality Co.,Ltd
Dr. Hashimoto is a graduate
of Osaka University Medical School. Following his postdoctoral
research at Harvard University Medical School, he became
an Associate Professor and Adjunct Professor at the University
of Pennsylvania. He also experienced Senior Director of
the Institute of Immunology, Syntex, Japan, Director, Biotechnology
Department of Roche (US) and Director of Molecular Biology
Department for the Tsukuba Laboratory of Nippon Glaxo Ltd
(currently GlaxoSmithKline K.K.). During Nippon Glaxo, he
was involved in PGx project planning.
In 2000, he founded MediBIC and is the President
and CEO to this day, serving Board of Director in several
Asian biotech companies, as well. |
Business
Management
| Takeshi Kanda
Executive Vice President, MediBIC Group
Executive Vice President, MediBIC
Executive Director, MediBIC Pharma
Executive Director, Site Quality Co.,Ltd
Mr.Kanda is a graduate of Waseda University
School of Commerce. In 2007, he founded Frontier Consulting
Japan Inc and is the President and CEO to this day. His
former experiences include Nikko Cordial Securities Inc
and Corporate Officer,Trans-Science Inc.
He joined MediBIC as an External Director in
March 2008, and was appointed Executive Vice President in
July. In August 2008, he was appointed Executive Vice President
of MediBic and Executive Director of MediBIC Pharma. He
was also appointed Executive Director, Site Quality Co.,Ltd
from Nov 2008. |
|
John Fou
External Director, MediBIC Group
Executive Director, Site Quality Co.,Ltd
Mr.Fou is a graduate of Princeton University
(major:Economics). He is the Co-founder and Representative
Director of Generation Group KK.
Formerly he worked for Baring Securities, and
was Executive Director, Securities Investment, at the Canadian
Imperial Bank of Commerce (CIBC), Director, Equity Trading
at Dresdner Kleinwort Wasserstein Securites,etc.
He joined MediBIC as an External Director in
March 2008. He was also appointed Executive Director, Site
Quality Co.,Ltd from Nov 2008.
|
Technology
Hiroki Nakae, Ph.D.
Executive Director, MediBIC Group
Dr. Nakae was a neuroscientst in Advanced
Research Lab., Toshiba Corp. Then a bioinformatician in
Life Science Group, Hitachi Ltd. responsible for R&D
and business development and the CEO of Canaledge Inc.
Dr. Nakae joined MediBIC as Managing Director,
Business Operation Division in January 2006.
In March 2007, he was appointed Executive Managing
Director, MediBIC Group.
From Sept 2008, he is the Executive Director of MediBIC
Group. |
Compliance
| Kazuo Usui, US C.P.A.
Statutory Auditor, MediBIC Group
Mr. Usui has experiences as Financial Manager
and Internal Audits of Chase Manhattan Bank, Advisor of
Nippon Becton Dickinson Co., Ltd, and President & CFO
of Fresenius Medical Care Japan Co. Ltd,
Mr. Usui joined MediBIC as a Statutory Auditor
from March 2006. |
|
Kazuharu Tomioka
Statutory Auditor, MediBIC Group
After working for the IPO department of Daiwa
Securities Co., Ltd, Mr. Tomioka established Disclosure
Inc. and was appointed CEO.
At Daiwa Securities, he made large-scale enlistments with
companies such as NTT DATA CORPORATION and Daini Denden
Inc. (currently KDDI CORPORATION) and enlisted over 50 other
companies.
Mr. Tomioka joined MediBIC in March 2003, and
after his role as Executive Director, he was appointed a
Statutory Auditor in March 2005.
He is also an Auditor for Invoice Inc. |
|
|
Akiyoshi Uchiyama, M.D., Ph.D.
Statutory Auditor, MediBIC Group
Dr. Uchiyama founded Artage, Inc in 2004 and
is the President to this day. He is also Deputy Director,
Development & Medical Affairs Division of GlaxoSmithKline
K. K.
After graduating Hamamatsu University, he joined
the Hamamatsu University Orthopedic Department followed
by a year at Harvard Medical School Orthopedic Research
as a post-doctoral fellow before joining Eisai Co. Ltd.
At GlaxoSmithKline, he is responsible for regulatory affairs,
drug safety, clinical development and compliance.
He joined MediBIC as a Statutory Auditor in
March 2008. |
|
